CryoCath tests new use for cryoablation system:
This article was originally published in Clinica
CryoCath Technologies has enrolled nine patients in a US study to assess a new clinical application for its Freezor cryoablation system. As an extension of the company's completed pivotal FROSTY trial, the new study will evaluate cryoablating, through the coronary venous system, a specific arrhythmia that the firm said was historically very difficult to treat with existing radiofrequency technology - epicardial posteroseptal accessory AV pathway. Data from the study will be added to the Montreal, Quebec firm's PMA application as part of the FDA review process to approve the Freezor system for the US market. CryoCath believes that the system will become commercially available in 2003.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.